Intravenous arketamine for treatment-resistant depression: Open-label pilot study
GC Leal, ID Bandeira, FS Correia-Melo… - European Archives of …, 2020 - Springer
Abstract
We aimed to analyze the efficacy and safety of arketamine, the R (−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary …
Authors
Last updated: Oct 05, 2020